12:00 AM
 | 
Apr 20, 2009
 |  BC Week In Review  |  Company News  |  Deals

Acuvax, RESprotect deal

Holding company Acuvax sold its 10% stake in cancer company RESprotect to an undisclosed European firm for an undisclosed sum. Acuvax said the deal would improve its cash position by over $750,000. RESprotect's pipeline includes RP101, a nucleoside...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >